Search the Newsreel

Oramed (ORMP) EPS and Revenue: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Post-Earnings: The Stock Ends Up 4.60% on the Day - Dividend Earnings Report

Sino Biopharmaceutical: Revenue up 10.6% to RMB19.44B, driven by 44.3% growth in innovative drugs and out-licensing

Danske Bank A S Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGN

Danske Bank A S has acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), purchasing 104,676 shares valued at approximately $65.27 million. This investment makes Danske Bank A S the owner of 0.10% of Regeneron Pharmaceuticals. The article also highlights recent analyst ratings, financial …

GSA Capital Partners LLP Invests $944,000 in BioMarin Pharmaceutical Inc. $BMRN

GSA Capital Partners LLP has invested $944,000 in BioMarin Pharmaceutical Inc. by acquiring 16,501 shares during the second quarter, making them a new institutional stakeholder. This move comes as other institutional investors have also adjusted their positions, and BioMarin continues to receive a "Moderate …

Amylyx Pharmaceuticals (AMLX) Is Up 48.6% After Positive Phase 3 Avexitide Data And $350M Equity Raise - Has The Bull Case Changed?

Price to earnings forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO

This article provides financial data for Phio Pharmaceuticals Corp. (NASDAQ: PHIO), specifically focusing on its price-to-earnings forward metric. It details the company's financial overview, including its stock market information on Nasdaq, and is presented within the TradingView platform context.

Rhythm Pharmaceuticals (RYTM) Could Be 14% Undervalued Following Its CMO Appointment

Rhythm Pharmaceuticals (RYTM) recently appointed Manher “AJ” Joshi, M.D., as Chief Medical Officer, signaling continued leadership in rare disease drug development. The company is currently trading at US$115.25, which is considered 14% undervalued compared to a narrative fair value of $134, primarily due to …

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of "Moderate Buy" from Brokerages

ANI Pharmaceuticals (NASDAQ:ANIP) has received an average "Moderate Buy" rating from eight brokerages, with four buy and four hold ratings. The company's average 12-month price target is $105.83, exceeding its current share price of $76.87. Recent quarterly results surpassed expectations, reporting $2.21 EPS against …

SENORES PHARMACEUTICALS L Share Price Hits One-Year High

REG - RTW Biotech Opp. - BioMarin to acquire Alesta Therapeutics

RTW Biotech Opportunities Ltd ("RTW Bio") announced that BioMarin Pharmaceutical Inc. is set to acquire Alesta Therapeutics, a clinical-stage biotechnology company. The deal includes an upfront cash payment of $275 million for Alesta's lead asset, ALE1, which represents a 41% uplift to RTW Bio's …

Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance

Amneal Pharmaceuticals (AMRX) has seen a 345.7% return over the past three years, leading to a valuation that appears fairly priced rather than an obvious bargain. While strong Q2 2026 results and raised full-year guidance support the current valuation, the stock trades at a …

Reaffirmed 2026 Guidance After Strong Q2 Could Be A Game Changer For Ligand Pharmaceuticals (LGND)

Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?

Xenon Pharmaceuticals recently reported wider Q2 2026 losses, reaching US$110.74 million, as it funds its ion-channel neurology pipeline, particularly ahead of the planned U.S. NDA submission for azetukalner. These rising losses bring funding needs and potential dilution into focus, prompting investors to assess the …

Inovio (INO) Earnings Check: The Available Earnings Metric Delivers a Beat at the Close; Post-Report Move: The Stock Ends Up 4.35% in the Latest Reading - Financial Data

Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock

Amylyx Pharmaceuticals (Nasdaq: AMLX) has announced a proposed underwritten public offering of $350.0 million of its common stock, with an option for underwriters to purchase an additional $52.5 million. The company plans to use the net proceeds, along with existing cash, for pre-commercial activities …

Recce Pharmaceuticals (ASX:RCE) Advances Phase 3 Trial With New Diabetic Foot Infection Study Design

Is Amneal Pharmaceuticals (AMRX) Fairly Valued After A 3.5x Return?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Amneal Pharmaceuticals stock has delivered very strong gains over the last few years, yet the broad valuation checks suggest it no longer looks like a …

Amylyx Pharmaceuticals, Inc. stock Analysis: August 2026 Surge & Outlook

Amylyx Pharmaceuticals, Inc. (AMLX) stock surged to $35.11 after its Phase 3 LUCIDITY trial for avexitide met all endpoints in post-bariatric hypoglycemia, leading to its best single-day performance in nearly four years. However, a concurrent $350.0 million public offering introduces dilution risk, complicating the …

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class S

Madrigal (NASDAQ: MDGL) awards Reed 647 RSUs and options on 1,078 shares

Madrigal Pharmaceuticals (NASDAQ: MDGL) director John C. Reed was granted 647 restricted stock units (RSUs) and options on 1,078 shares. The RSUs will vest 50% on August 15, 2027, and 50% on August 15, 2028, while the stock options, with an exercise price of …

What's Going On With Cipher Pharmaceuticals Inc Stock Tuesday?

Amylyx (AMLX) Climbs to Fresh High as Avexitide Moves Closer to Commercialization

Amylyx Pharmaceuticals (AMLX) stock surged to a new three-year high following strong Phase 3 clinical trial results for its drug candidate Avexitide, a treatment for post-bariatric hypoglycemia (PBH). The drug successfully reduced low-blood-sugar episodes by 55% and met all secondary endpoints, leading to increased …

Aurinia (AUPH) Earnings Metrics: EPS Comes in Above Forecast in the Current Update; Trading-Day Reaction: Shares Move 0.07% Up - Quarterly Profit Report

Supernus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SUPN)

Recursion (NASDAQ: RXRX) CSO sees 26K shares withheld for taxes

Recursion Pharmaceuticals (NASDAQ: RXRX) Chief Scientific Officer David Hallett had 26,657 shares of Class A common stock withheld on August 17, 2026, to satisfy tax obligations related to the net settlement of restricted stock units. This action was solely for tax purposes and not …

Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares of Stock

Verrica Pharmaceuticals' (NASDAQ:VRCA) Chief Marketing Officer, Noah Rosenberg, purchased 4,200 shares of the company's stock for $20,622, increasing his direct ownership by 178.19%. This transaction occurred as VRCA shares traded down, below their 50-day and 200-day moving averages. The company holds an $80.4 million …

Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Acquires 5,000 Shares

Verrica Pharmaceuticals CEO Jayson Rieger recently purchased 5,000 shares of the company's stock for $24,550, increasing his total ownership to 207,593 shares. This transaction occurred as the stock fell 4.3% to $4.68, bringing its market capitalization to approximately $80.4 million. The company has mixed …

VRCA Looks 50.3% Undervalued on GF Value™ Despite Profitability Challenges

Verrica Pharmaceuticals Inc (NASDAQ: VRCA) saw its CEO purchase 25,000 shares, leading to a 7.5% after-hours price increase and renewed investor interest despite ongoing profitability challenges. While the GF Value™ suggests VRCA is 50.3% undervalued, this should be viewed cautiously given the company's negative …

Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors

Corbus Pharmaceuticals Holdings Inc. (CRBP) stock dropped 3.91% on Tuesday, closing at $10.08. This underperformance occurred during a general market downturn, with both the NASDAQ Composite Index and Dow Jones Industrial Average also experiencing losses. The decline ended a five-day winning streak for the …

Arrowhead (NASDAQ: ARWR) director to sell 2,000 shares

A director at Arrowhead Pharmaceuticals Inc. (ARWR), Adeoye Olukotun, has filed a Rule 144 notice to sell 2,000 shares of common stock through Merrill Lynch. The proposed sale, valued at $173,876.47, is expected around August 18, 2026, on NASDAQ. These shares were originally acquired …

Mirum Pharma (NASDAQ: MIRM) officer lines up $4M share sale

Jolanda Marie Howe, an officer at Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), has filed a Form 144 to sell 40,000 common shares valued at $4,000,000.00 on August 18, 2026, following a stock option exercise. The sale will be executed through Morgan Stanley Smith Barney. The …

Processa Pharmaceuticals (NASDAQ: PCSA) gains new 5.8% owner with no sole control

Soleus Capital Master Fund, L.P. and related entities, including Guy Levy, have reported a beneficial ownership of 160,943 shares of Processa Pharmaceuticals (PCSA), representing 5.8% of the outstanding common stock. This ownership grants shared voting and dispositive power but no sole control. The filing …

Rhythm (RYTM) CMO reports no company stock holdings

Rhythm Pharmaceuticals, Inc. (RYTM) Chief Medical Officer, Joshi Manher, has filed an initial statement of beneficial ownership (Form 3) indicating no equity transactions or holdings in the company. The filing includes an Exhibit 24 for a Power of Attorney, allowing filings to be made …

Rhythm Pharmaceuticals (RYTM) grants CMO 50K options expiring 2036

Rhythm Pharmaceuticals (RYTM) has granted its Chief Medical Officer, Manher Joshi, 50,000 stock options with an exercise price of $115.44, expiring in 2036, and 25,000 Restricted Stock Units (RSUs). The stock options vest over four years, while the RSUs vest annually from 2027 to …

Recursion Pharmaceuticals Inc (RXRX) News, Articles, Events & Latest Updates

MIRA (MIRA) Financial Results: The Company Lists Its Latest Available Figures in the Latest Session; Investor Response: Shares Fall 3.16% in the Latest Reading - Segment Revenue Breakdown